KLRK1 and neoplasm: Low PD-L1 and MHC1 expression, low level of ligands for NK cell activating receptor NKG2D and paucity of immune cells in the tumor microenvironment (TME) are some of the likely contributors to immunotherapy resistance in SCLC5–9.